Continuous positive airway pressure “is here to stay,” sleep medicine doctor Atul Malhotra declared in a May 2024 editorial published in the Lancet.
But after Eli Lilly reported the full results of its obesity drug in sleep apnea patients last week, industry watchers are now debating the lasting power of CPAP machines. The trial, run by Malhotra himself, demonstrated that Zepbound reduced the number of sleep apnea episodes in patients both who were using the machines and those who were not.
Investors swiftly reacted after the data release on late Friday. On Monday, shares of leading CPAP maker ResMed dropped 11% and shares of nerve stimulator Inspire sank 17%. But industry analysts and clinical experts are split on whether this is another example of “Ozempic panic,” or a legitimate warning of CPAP’s eventual decline.
Click this link for the original source of this article.
Author: Lizzy Lawrence and Elaine Chen
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.